Alpha Profiles · Company Profile

PDS Biotechnology Corp

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/pds-biotechnology-corp

Entity: Public listing published
Primary listing: NASDAQ: PDSB
Verification: Partially verified
Last reviewed: 2026-09-13T04:47:06.014709+00:00

Overview

Alpha's canonical identity and public leadership record for PDS Biotechnology Corp.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

6 public records

Frank Bedu-Addo, Ph.D.

President, Chief Executive Officer, Principal Executive Officer and Director

State: confirmed
Effective: From Mar 30, 2026
Confidence: 94%
Evidence: PDSB 10-K executive officersMar 30, 2026

Gregory L. Conn, Ph.D.

Chief Scientific Officer

State: confirmed
Effective: From Mar 30, 2026
Confidence: 94%
Evidence: PDSB 10-K executive officersMar 30, 2026

Kirk V. Shepard, M.D.

Chief Medical Officer

State: confirmed
Effective: From Mar 30, 2026
Confidence: 94%
Evidence: PDSB 10-K executive officersMar 30, 2026

Lars Boesgaard

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

State: confirmed
Effective: From Mar 30, 2026
Confidence: 94%
Evidence: PDSB 10-K executive officersMar 30, 2026

Spencer Brown

Senior Vice President, General Counsel, Chief Compliance Officer

State: confirmed
Effective: From Mar 30, 2026
Confidence: 94%
Evidence: PDSB 10-K executive officersMar 30, 2026

Stephan Toutain

Chief Operating Officer

State: confirmed
Effective: From Mar 30, 2026
Confidence: 94%
Evidence: PDSB 10-K executive officersMar 30, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 13, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.